RGRX (Regenerx Biopharmaceuticals) EBITDA Margin %: -1,605.26% (As of Mar. 2023)


What is Regenerx Biopharmaceuticals EBITDA Margin %?

Regenerx Biopharmaceuticals RGRX EBITDA Margin % is -1,605.26% as of Mar. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Regenerx Biopharmaceuticals's EBITDA for the three months ended in Mar. 2023 was $-0.31 Mil. Regenerx Biopharmaceuticals's Revenue for the three months ended in Mar. 2023 was $0.02 Mil. Therefore, Regenerx Biopharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2023 was -1,605.26%.

Regenerx Biopharmaceuticals  (OTCPK:RGRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Regenerx Biopharmaceuticals EBITDA Margin % Related Terms

Regenerx Biopharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals EBITDA Margin % Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,720.00 -1,622.08 -1,676.62 -1,653.25 -1,820.78

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,810.53 -2,447.37 -1,494.74 -1,626.32 -1,605.26

RGRX vs MYMX, RGMP, NBRVF: EBITDA Margin % Comparison

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerx Biopharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's EBITDA Margin % falls into.


Regenerx Biopharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Regenerx Biopharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-1.402/0.077
=-1,820.78 %

Regenerx Biopharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-0.305/0.019
=-1,605.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,605.26% mean?
Regenerx Biopharmaceuticals (RGRX) has a EBITDA Margin % of -1,605.26% as of Mar. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' EBITDA Margin % too high?
Regenerx Biopharmaceuticals' current EBITDA Margin % is -1,605.26%.
How does Regenerx Biopharmaceuticals' EBITDA Margin % compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' EBITDA Margin % of -1,605.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current EBITDA Margin % is -1,605.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current EBITDA Margin % of -1,605.26%. The current EBITDA Margin % is -1,605.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current EBITDA Margin % is -1,605.26% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.